组胺-2受体拮抗剂与胃癌

Histamine-2 receptor antagonists and gastric cancer.

作者信息

Johnson A G, Jick S S, Perera D R, Jick H

机构信息

Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.

出版信息

Epidemiology. 1996 Jul;7(4):434-6. doi: 10.1097/00001648-199607000-00016.

DOI:10.1097/00001648-199607000-00016

PMID:8793372

Abstract

We conducted a case-control study at Group Health Cooperative of Puget Sound to evaluate the relation between longterm histamine-2 (H2) receptor antagonist use and gastric cancer. We identified 113 cases and 452 controls and estimated a relative risk (RR) of 2.0 [95% confidence interval (C1) = 1.0-3.9]. When we evaluated the effect of time-since-first-use, the RR estimates were 6.5, 1.2, and 1.0 for 2-4 years of use, 5-9 years, and > or = 10 years, respectively. The data provide substantial evidence that long-term H2 antagonist use is not associated with gastric cancer.

摘要

我们在普吉特海湾健康合作组织开展了一项病例对照研究，以评估长期使用组胺-2（H2）受体拮抗剂与胃癌之间的关系。我们确定了113例病例和452名对照，并估计相对风险（RR）为2.0[95%置信区间（CI）=1.0 - 3.9]。当我们评估首次使用后的时间效应时，使用2 - 4年、5 - 9年以及≥10年的RR估计值分别为6.5、1.2和1.0。这些数据提供了充分证据，表明长期使用H2拮抗剂与胃癌无关。